CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021
March 16 2021 - 4:05PM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, announced today that the
company will release its fourth quarter 2020 financial results
after the market closes on Tuesday, March 30, 2021. Management will
host a conference call with a slide presentation at 5:00 p.m. ET
(2:00 p.m. PT) on the same day to provide an update on the
company’s business.
Details for the Conference Call and Slide
Presentation:
Date: March 30, 2021Time: 5:00 p.m. ET (2:00 p.m. PT)
Conference Audio
- Dial-in U.S. and Canada: (877) 451-6152
- Dial-in International: (201) 389-0879
- Conference ID No.: 13717040
Slide Presentation
- Go to www.webex.com, click on the ‘Join a Meeting’ button and
enter meeting number 145 355 3814 and password CWBR, or
- Go to www.cohbar.com and click on Q4 2020 Shareholder
Presentation at the top of homepage.
For individuals participating in the Investor Call and Slide
Presentation, please call into the conference audio and log into
Webex approximately 10 minutes prior to its start.
An audio replay of the call will be available beginning at 8:00
p.m. Eastern Time on March 30, 2021, through 11:59 p.m. Eastern
Time on April 20, 2021. To access the recording please dial (844)
512-2921 in the U.S. and Canada, or (412) 317-6671 internationally,
and reference Conference ID# 13717040. The audio recording along
with the slide presentation will also be available at
www.cohbar.com during the same period.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company
focused on the research and development of mitochondria based
therapeutics, an emerging class of drugs for the treatment of
chronic and age-related diseases. Mitochondria based therapeutics
originate from the discovery by CohBar’s founders of a novel group
of naturally occurring peptide sequences within the mitochondrial
genome, some of which have been shown to have the
potential to regulate key processes
in multiple systems and organs in the body. To date,
the company has discovered more than 100 mitochondrial derived
peptides and generated over 1,000 analogs. CohBar’s efforts focus
on the development of these peptides into therapeutics that offer
the potential to address a broad range of diseases associated
with the underlying impact of mitochondrial dysfunction. The
company’s lead compound, CB4211, is in the Phase 1b stage of a
Phase 1a/1b clinical trial for NASH and obesity. In addition,
CohBar has four preclinical programs: CB5138 Analogs for
fibrotic diseases, CB5064 Analogs for COVID-19 associated
ARDS, CB5046 Analogs for CXCR4-related cancer and orphan diseases,
and MBT3 Analogs for cancer immunotherapy.
For additional company information, please visit
www.cohbar.com.
Contacts:
Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650)
445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024